SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pseudo Biologist who wrote (630)10/23/2000 1:32:49 PM
From: berblady  Read Replies (1) of 666
 
Many thanks for your enthusiastic welcome.

Thanks also for the link to that article. It is most interesting. Several on the Yahoo board have asked why Gillis left Immunex. This article provides one "answer". To whit:

"But Gillis said he reluctantly left the top-notch research team he helped establish at Immunex because he liked the idea of building companies from the ground up. Corixa was the perfect opportunity to move in a slightly different direction."

O.K. But. If he helped build Immunex from the ground up, why did he leave to build another from the ground up? And if that's the pattern, when does he leave Corixa to build another company from the ground up?

Although the article is a couple of years old, it does provide a good deal of insight into the kind of company Corixa is, or was. I'm not sure if its mission and goals are the same as they were in 1998.

Unfortunately, I don't understand (at an informed layman's level) the science behind Corixa's technologies. I'd greatly appreciate all the help I can get.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News